Mirataz
Active substance
ATC code
Species
Cats.
Indications
For body weight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions (see section 5.1).
Dose to be administered and administration route
Transdermal use.
The veterinary medicinal product is applied topically to the inner pinna (inner surface of the ear) once daily for 14 days, at the dosage of 0.1 g ointment/cat (2 mg mirtazapine/cat). This corresponds to a 3.8 cm line of ointment (see below).
Alternate the daily application between the left and right ears. If desired, the inner surface of the cat’s ear may be cleaned by wiping with a dry tissue or cloth immediately prior to the next scheduled dose. If a dose is missed, apply the veterinary medicinal product the following day and resume daily dosing.
The recommended fixed dose has been tested in cats weighing between 2.1 kg and 7.0 kg.
To apply the veterinary medicinal product:
Step 1: Put on impermeable gloves | Step 2: Twist cap on tube anticlockwise to open. | Step 3: Apply even pressure on tube and squeeze a 3.8 cm line of ointment onto your index finger using the measured line on the carton/bottle or in this leaflet as a guide. | Step 4: Using your finger, gently rub ointment on inside surface of cat’s ear (pinna) spreading it evenly over the surface. If contact with your skin occurs wash with soap and water. |
The line below coincides with the appropriate length of ointment to be applied:
Adverse reactions
Application site reaction(s) (erythema, crust/scab, residue, scaling/dryness, flaking, head shaking, dermatitis or irritation, alopecia, and pruritus) and behavioural changes (increased vocalisation, hyperactivity, disoriented state or ataxia, lethargy/weakness, attention seeking and aggression) occurred very commonly in safety and clinical studies.
Vomiting, polyuria associated with reduced urine specific gravity, elevated blood urea nitrogen (BUN) and dehydration were commonly observed in safety and clinical studies. Depending on the severity of vomiting, dehydration or behavioural changes, administration of the product may be discontinued according to the benefit-risk assessment of the veterinarian.
These adverse events, including local reactions, resolved at the end of treatment period with no specific treatment.
In rare occasions, hypersensitivity reactions can occur. In these cases, the treatment should be immediately withdrawn.
In case of oral ingestion, in addition to effects cited above (except local reactions), salivation and tremors may rarely occur.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 4.7 Use during pregnancy, lactation or lay
Mirtazapine has been identified as potentially reprotoxic in rats and rabbits.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Pregnancy and lactation:
Do not use during pregnancy and lactation (see section 4.3).
Fertility:
Do not use in breeding animals (see section 4.3).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | |
| EAN | 5701170432015 |
